top of page

The powerhouse of the cell

Driving a new means of fighting disease

Overview of our Patent-Pending MOT™ Technology

While conducting cancer research in the U.S., the benefits of mitochondria transplantation were discovered and exclusively licensed to MitoSense, under the name Mitochondria Organelle Transplantation (MOT™).  During the past two years, MOT™ has shown tremendous promise in early research and testing. This early evidence indicates MOT™ may alleviate some symptoms associated with neurodegenerative disorders such as ALS, Alzheimer’s, Parkinson’s, and others. Further research and testing are under way.

There is currently no other therapy available like MOT™ and the early indications point to much broader applications, that could benefit millions of Americans suffering from various neurodegenerative issues and diseases. 

Watch the promise of Mitochondria Organelle Transplantation (MOT™) to fight neurodegenerative diseases.

Validating Science

Path Forward

We are actively forming partnerships with various public and private institutions  to expand our research and reach, so we can help improve as many lives as possible.

bottom of page